Corrigendum: Immune Responses to Gametocyte Antigens in a Malaria Endemic Population—The African falciparum Context: A Systematic Review and Meta-Analysis by Muthui, Michelle K. et al.
CORRECTION
published: 23 March 2020
doi: 10.3389/fimmu.2020.00389
Frontiers in Immunology | www.frontiersin.org 1 March 2020 | Volume 11 | Article 389
Edited and reviewed by:
Ian Marriott,
University of North Carolina at
Charlotte, United States
*Correspondence:
Michelle K. Muthui
mmuthui@kemri-wellcome.org
Specialty section:
This article was submitted to
Microbial Immunology,
a section of the journal
Frontiers in Immunology
Received: 15 January 2020
Accepted: 19 February 2020
Published: 23 March 2020
Citation:
Muthui MK, Kamau A, Bousema T,
Blagborough AM, Bejon P and
Kapulu MC (2020) Corrigendum:
Immune Responses to Gametocyte
Antigens in a Malaria Endemic
Population—The African falciparum
Context: A Systematic Review and
Meta-Analysis.
Front. Immunol. 11:389.
doi: 10.3389/fimmu.2020.00389
Corrigendum: Immune Responses to
Gametocyte Antigens in a Malaria
Endemic Population—The African
falciparum Context: A Systematic
Review and Meta-Analysis
Michelle K. Muthui 1*, Alice Kamau 1, Teun Bousema 2,3, Andrew M. Blagborough 4,5,
Philip Bejon 1,6 and Melissa C. Kapulu 1,6
1Department of Biosciences, KEMRI-Wellcome Trust Programme, Kilifi, Kenya, 2 Immunology and Infection Department,
London School of Hygiene and Tropical Medicine, London, United Kingdom, 3 Radboud Institute for Health Sciences,
Radboud University Medical Center, Nijmegen, Netherlands, 4Department of Life Sciences, Imperial College London,
London, United Kingdom, 5Department of Pathology, University of Cambridge, Cambridge, United Kingdom, 6Nuffield
Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, United Kingdom
Keywords: immunity, Plasmodium falciparum, gametocytes, Pfs230, Pfs48/45
A Corrigendum on
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byMuthui, M. K., Kamau, A., Bousema, T., Blagborough, A. M., Bejon, P., and Kapulu, M. C. (2019).
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In the original article, there were errors in Tables 1, 2 and 3, and to the text. In Table 1, one of
the two study sites from Amoah et al.’s study (Parasites & Vectors, 2018) was erroneously excluded
from the table hence the study was presented as one site, the age range of study participants from
the Stone et al. (Nature Communications, 2018) study site “Hauts-Bassins (Burkina Faso)” was
mistakenly indicated as “2–74” instead of “5–14” years and the reference for Skinner et al. given as
“35” instead of “33”. These errors have been corrected and the amended table appears in this article.
Furthermore, owing to the omission of the study site from Amoah et al.’s study, the figures
quoted in the text on the overall number of study sites and the total number of study sites
reporting seroprevalence to Pfs230 and Pfs48/45 were incorrect. The total number of study sites
for Pfs230 was given as “14” instead of “15” and for Pfs48/45 given as “14” instead of “13”. Also, we
inadvertently provided the total number of individual study locations (“23”) instead of the study
sites—based on administrative region—(“17”) when providing a summary of the 12 studies that we
included in the analysis. In addition, the citation for “Amoah et al.” was was incorrectly cited as
“Acquah et al.” in the Results section, sub-section Pfs230, Seroprevalence, Paragraph 1.
These errors have been corrected and amendments made to the relevant result sections,
given below.
Results section, sub-section Study Selection and Characteristics, Paragraph 1:
“The 12 studies were carried out across 17 study sites, majority of which were in West Africa
(Burkina Faso, Senegal, Gabon, Cameroon, Ghana, andMali) with only one study site in East Africa
(Tanzania) and two study sites in Southern Africa (Zimbabwe) (Table 1). Ten articles (from 15
study sites) measured responses to Pfs230 and nine articles (13 study sites) measured responses to
Pfs48/45. Six studies were longitudinal studies spread over the malaria transmission season with all
but one measuring responses to both Pfs230 and Pfs48/45. Studies predominantly used ELISA as
the immunoassay with only one study measuring responses using protein microarrays.”
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TABLE 1 | Characteristics of studies included in the systematic review and meta-analysis.
Study
(Reference)
Year Country Region of
study sitec
Sample
size
Age group
(years)
Antigen
detected
Seasonality
tested (Y/N)
Assay Seropositivity
cut-off
Negative
controld
Selective
recruitmente
Amoah et al.
(34)a
2018 Ghana
(Abura)
Central 65 6–12 Pfs230 No ELISAR 2 SD Naïve No
Amoah et al.
(34)a
2018 Ghana
(Obom)
Greater Accra 75 6–12 Pfs230 No ELISAR 2 SD Naïve No
Lamptey et al.
(35)
2018 Ghana Greater Accra 338 2–65 Pfs230 Yes ELISAR 3 SD Test sample No
Stone et al.
(20)b*
2018a Burkina Faso Hauts-
Bassins
33 5–14 Pfs230 and
Pfs48/45
No ELISAR 3 SD Test sample Yes
Stone et al.
(20)b*
2018b Burkina Faso Centre-Nord 38 2–10 Pfs230 and
Pfs48/45
No ELISA 3 SD Test sample Yes
Stone et al.
(20)b*
2018 Cameroon Centre 140 5–16 Pfs230 and
Pfs48/45
No ELISAR 3 SD Test sample Yes
Bansal et al.
(42)
2017 Zimbabwe Mashonaland
Central
181 6–14 Pfs48/45 No ELISAR 2 SD Naïve No
Paul et al. (43) 2016 Zimbabwe Manicaland 150 6–16 Pfs48/45 No ELISAR 2 SD Naïve No
Ateba-Ngoa
et al. (44)b
2016 Gabon Moyen -
Ogooue
286 3–50 Pfs230 and
Pfs48/45
No ELISAR 3 SD Test sample No
Jones et al.
(19)b
2015 Burkina Faso Nord 200 5–16 Pfs230 and
Pfs48/45
Yes ELISAR 3 SD Test sample No
Jones et al.
(19)b
2015 Ghana Greater Accra 108 5–17 Pfs230 and
Pfs48/45
Yes ELISAR 3 SD Test sample No
Jones et al.
(19)b
2015 Tanzania Tanga Region 202 3–15 Pfs230 and
Pfs48/45
Yes ELISAR 3 SD Test sample No
Skinner et al.
(33)b
2015 Mali Koulikoro 3
and Bamako
225 2–25 Pfs230 and
Pfs48/45
Yes MicroarrayR 2 SD No
Template
No
Miura et al.
(45)
2013 Mali Kayes 2 45 18–60 Pfs230 No ELISAR 3 SD Naïve No
Ouedraogo
et al. (24)b*
2018 Burkina Faso Centre-Nord 128 1–55 Pfs230 and
Pfs48/45
Yes Two-site
ELISAGe
3 SD Naïve No
Ouedraogo
et al. (16)a
2011 Burkina Faso Centre-Nord 296 1–>20 Pfs230 and
Pfs48/45
Yes Two-site
ELISAGe
2 SD Naïve No
Van der Kolk
et al. (46)
2006 Cameroon Centre 236 5–14 Pfs230 and
Pfs48/45
No Two-site
ELISAGe
2 SD Naïve No
aSeroprevalence data provided by authors upon request.
bSeroprevalence data calculated from data provided by original authors, or from data available on public repositories.
b*Citation also includes citation of repository from which data was retrieved.
cAdministrative region of study site from which participants were drawn, this was used infer predicted parasite prevalence rates standardized in 2 – 10-year olds (PfPR2−10 ) that was
then used to assign transmission intensity at the time of sampling.
dNegative control refers to the comparator used to assign seropositivity in the immunoassay. Naïve – malaria naïve volunteers; Sample – a proportion of statistically – defined seronegative
individuals; No template - a ‘no DNA control’ used to detect reactivity to the expression vector used to produce protein for the array.
eSelective recruitment refers to studies that only recruited parasite positive individuals for antibody measurements.
RRecombinant protein; Gegametocyte extract.
SD, standard deviation.
TABLE 2 | Univariable meta-regression analysis of factors influencing reported seroprevalence to Pfs230.
No. of studies
(No. of Sites)
Coefficient (β) Lower CI Upper CI p-value* Residual I2 I2 change (%)
Age
Children (ref.) 10 (14)
Adults 6 (6) 0.21 0.05 0.38 0.04 95.36 2.09
Asexual parasite
prevalence
6 (10) −0.001 −0.005 0.002 0.51 95.37 2.08
Gametocyte prevalence 4 (8) −0.002 −0.004 0.001 0.38 92.54 4.50
Transmission intensity
Mesoendemic (ref.) 7 (8)
Hyperendemic 6 (7) −0.06 −0.23 0.11 0.51 96.18 1.25
(Continued)
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TABLE 2 | Continued
No. of studies
(No. of Sites)
Coefficient (β) Lower CI Upper CI p-value* Residual I2 I2 change (%)
Season
Dry (ref.) 6 (9)
Rainy 5 (7) 0.07 −0.12 0.27 0.51 96.24 1.19
Assay
ELISA (ref.) 6 (11)
Microarray 1 (1) 0.31 0.08 0.55 0.07 95.29 2.17
Two-site ELISA 3 (3) 0.12 −0.06 0.29
Antigen
Gametocyte extract (ref.) 3 (3)
Recombinant protein 7 (12) −0.06 −0.25 0.13 0.51 96.31 1.12
Antigen concentration+
0.1µg/ml (ref.) 3 (7)
1µg/ml 3 (4) 0.26 0.09 0.43 0.04 93.52 3.98
Seropositivity cut-off
2 SD (ref.) 4 (5)
3 SD 6 (10) −0.22 −0.37 −0.06 0.04 95.16 2.30
*p-values adjusted using the Benjamini and Hochberg correction for multiple testing; values in bold p < 0.05.
+ Antigen concentration was only tested for studies using recombinant protein as antigen source.
CI, confidence interval; SD, standard deviation.
TABLE 3 | Univariable meta-regression analysis of factors influencing reported seroprevalence to Pfs48/45.
No. of Studies
(No. of Sites)
Coefficient (β) Lower CI Upper CI p-value Residual I2 I2 change (%)
Age
Children (ref.) 9 (13)
Adults 4 (4) 0.07 −0.12 0.27 0.49 94.90 −0.18
Asexual parasite
prevalence
4 (8) −0.003 −0.006 0.0003 0.11 91.41 3.96
Gametocyte prevalence 4 (8) −0.003 −0.005 −0.002 0.003 70.82 25.24
Transmission intensity
Hypoendemic (ref.) 1(1)
Mesoendemic 5 (6) −0.47 −0.89 −0.06 0.11 93.91 0.87
Hyperendemic 5 (6) −0.38 −0.80 0.04
Season
Dry (ref.) 4 (6)
Rainy 6 (8) 0.07 −0.09 0.24 0.47 93.12 1.70
Assay
ELISA (ref.) 5 (9)
Microarray 1 (1) 0.36 0.15 0.56 0.016 91.99 2.89
Two-site ELISA 3 (3) 0.09 −0.07 0.24
Antigen
Gametocyte extract (ref.) 3 (3)
Recombinant protein 6 (10) −0.01 −0.19 0.17 0.91 94.91 −0.19
Antigen concentration+
0.1µg/ml (ref.) 3 (7)
1µg/ml 2 (2) 0.30 0.06 0.54 0.043 92.65 2.20
Seropositivity cut-off
2 SD (ref.) 5 (5)
3 SD 4 (8) −0.26 −0.39 −0.12 0.003 91.38 3.54
*p-values adjusted using the Benjamini and Hochberg correction for multiple testing; values in bold p < 0.05.
+Antigen concentration was only tested for studies using recombinant protein as antigen source.
CI, confidence interval; SD, standard deviation.
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Results section, sub-section Pfs230, Seroprevalence,
Paragraph 1:
“Ten studies from across 15 study sites in Africa analyzed
immune responses to Pfs230. The range of seroprevalence
estimates was quite wide, ranging from 6% reported by Stone
et al. in Soumousso and Dande villages, Burkina Faso (20)
to 72% reported by Amoah et al. (34) (Figure 2). Significant
heterogeneity was observed between the studies (I2 = 97%; 95%
CI: 96–98%; p< 0.01) therefore, a pooled prevalence estimate was
not calculated.”
Results section, sub-section Pfs48/45, Seroprevalence,
Paragraph 1:
“A total of 9 studies carried out over 13 study sites measured
immune responses to Pfs48/45. The range of seroprevalence
estimates reported was 0% from Stone et al.’s study sites in
Burkina Faso (20) to 64% reported by Paul et al. from their
study in the Makoni district in Zimbabwe (43). As with Pfs230,
there was significant heterogeneity between the studies, I2 =96%
(95% CI: 95–97%), and hence no pooled estimate was calculated
(Figure 3).”
Additionally, there were errors in Table 2 and Table 3,
regarding the values for the No. of Studies (No. of Sites) under
the variable Antigen. For Table 2, the numbers were switched
around for gametocyte extract and recombinant protein and
hence the numbers for Gametocyte extract read “7 (12)” instead
of “3 (3)” and under the variable Recombinant protein read
“3 (3)” instead of “7 (12).” For Table 3 one study was missing
from the count hence the value for the No. of Studies (No. of
Sites) under the variable Recombinant protein read “5 (10)”
instead of “6 (10).” The corrected Tables 2 and 3 appear in
this article.
The authors apologize for these errors and state that this does
not change the scientific conclusions of the article in any way.
The original article has been updated.
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